Mancini Anthony sold 37.4K shares of RVMD for $3.6M across 5 transactions on 2026-03-25, reducing stake 40.8%
Mancini Anthony executed 5 separate sales totaling 37,450 shares for $3,578,820.59 at a blended average price of $95.56, reducing his holdings from 91,850 shares to 54,400 shares. This represents a 40.8% reduction in his position. The sales occurred at prices ranging from $93.22 to $97.21, and notably occur when the current stock price ($93.21) sits 24.4% below the 52-week high of $123.27 and has declined 11.1% over the past 30 days. Revolution Medicines remains unprofitable with a net loss of $305,206,000 in its latest full fiscal year and zero revenue in the latest quarter, consistent with its early-stage biotech profile. The scale and breadth of this divestiture—reducing near-half of his position—warrants investor attention given the company's current financial trajectory.